Mental-Illness Medical Cannabis Studies

A

• addiction (10)

• alzheimers/dementia (14)

• amyotrophic-lateral-sclerosis-als-lou-gehrigs (2)

• antibacterial (6)

• antioxidant (8)

• antiprion (1)

• anxiety (10)

• appetite (4)

• arthritis (4)

• asthma (1)

• attention-deficit-hyperactivity-disorder-adhd (5)

• autism (11)

• autoimmune (3)

B

• batten-disease (6)

• benefits (9)

• breast-cancer (7)

C

• cancer (94)

• cannabidiol-cbd (8)

• cardiovascular (8)

• cb1-receptor (8)

• cb2-receptor (9)

• cellular-function (4)

• cerebral-palsy (1)

• cognition (2)

• colon-cancer (8)

D

• d9-tetrahydrocannabinol-thc (4)

• d9-tetrahydrocannabinolic-acid-thca (1)

• diabetes (4)

• drug-interactions (2)

E

• emesis (6)

• endocannabinoid-system-ecs (45)

• endocrine-system (3)

• epilepsy (30)

F

• fibromyalgia (2)

• fibrosis (1)

G

• gastrointestinal-disease (6)

• general (20)

• glaucoma (1)

• glioblastoma (1)

• glioma (9)

H

• health-care (1)

• hiv (7)

• huntingtons-disease (1)

I

• immune-function (8)

• infant-development (1)

• inflammation (9)

• ischemia (3)

K

• krabbe-disease (4)

L

• liver (2)

• lung-cancer (2)

• lupus (1)

M

• memory (3)

• mental-illness (14)

• migraine (1)

• mitochondria (1)

• multiple-sclerosis (15)

N

• national-institute-on-drug-abuse-nida (1)

• nausea (1)

• nervous-system (4)

• neuro-protective-and-neuro-generative (7)

P

• pain (29)

• pancreatitis (1)

• prostate-cancer (2)

S

• schizophrenia (2)

• skin (1)

• sports (3)

T

• thc (1)

• therapeutic (1)

• traumatic-brain-injury-tbi (1)

• View All (505)
  • Brain CB2 Receptors: Implications for Neuropsychiatric Disorders (2010)

    The CB2 receptor as a possible target for the treatment of neuroinflammatory and neurodegenerative disorders. View study

  • Cannabidiol as a potential treatment for psychosis (2013)

    A review that concisely describes the role of the endocannabinoid system in the development of psychosis and provides an overview of several currently available studies on the antipsychotic properties of CBD. View study

  • Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia (2012)

    CBD is a component of cannabis that moderately inhibits the degradation of endocannabinoid anandamide. These results indicate that the inhibition of the deactivation of anandamide contributes to the antipsychotic effects of CBD, which could suggest a novel mechanism in the treatment of schizophrenia. View study

  • Cannabidiol for the treatment of psychosis in Parkinson's disease (2008)

    One of the biggest challenges faced by doctors against Parkinson’s disease is the treatment of psychosis, which is why the treatment with CBD has been suggested due to its antipsychotic and neuroprotective effects. In this study, its efficacy was evaluated and demonstrated. View study

  • Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice (2005)

    Cannabidiol acts as an agonist of the vanilloid channel 1 in the transient receptor potential family (TRPV1) and also to inhibit the hydrolysis and cellular uptake of the endogenous cannabinoid anandamide. Cannabidiol also has potential as an antipsychotic. View study

  • Cannabidiol reverses the mCPP-induced increase in marble-burying behavior (2013)

    Cannabidiol (CBD), one of the main components of Cannabis sp., Shows clinical and preclinical anxiolytic properties. This study was based on investigating the interference of (CBD) in the effects of metachlorophenylpiperazine (mCPP), in repetitive burial. View study

  • Cannabinoid CB1 receptors in the dorsal hippocampus and prelimbic medial prefrontal cortex modulate anxiety-like behavior in rats: Additional evidence (2014)

    In the present study we want to verify if interfering directly with the metabolism and reuptake of the endocannabinoids (BCE), in the pre-limbic (PL) portion of the medial prefrontal cortex (PFC) (MPFC) and dorsal HIP (dHIP) would produce different effects in Two conceptually different animal models: the highest labyrinth (EPM) and the Vogel conflict test (VCT). View study

  • Cortical glutamic acid decarboxylase 67 deficiency results in lower cannabinoid 1 receptor messenger RNA expression- implications for schizophrenia (2012)

    It was concluded in this study that the findings that reduce the expression of glutamic acid ribonucleic acid (mRNA) (GAD67), can induce a lower expression of cannabinoid receptor 1 mRNA (CB1R), support the hypothesis that cortical levels Lower CB1R levels in schizophrenia can partially compensate for the deficiency of GABA-mediated gamma amino butyric acid (GABA) synthesis by reducing the suppression of endogenous cannabinoids from GABA release. View study

  • Distinct Neurobehavioural Effects of Cannabidiol in Transmembrane Domain Neuregulin 1 Mutant Mice (2012)

    Through this study we want to verify if the mutant neuregulin 1 transmembrane mice (Nrg1 TM HET) respond differently to cannabis (CBD) and if the (CBD) reverts the phenotypes related to schizophrenia expressed by these mice. View study

  • Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain (2014)

    View study

  • Joint Effects: A Pilot Investigation of the Impact of Bipolar Disorder and Marijuana Use on Cognitive Function and Mood (2016)

    The objective of this research was to determine the impact of marijuana on mood in bipolar patients and to verify if marijuana confers an additional negative impact on cognitive function. View study

  • Motor effects of delta 9 THC in cerebellar Lurcher mutant mice (2007)

    In the study, the motor effects of delta 9 tetrahydrocannabinol (delta 9 THC) were evaluated in Lurcher brain mutant mice. It was observed that cannabinoid substance (CB) reduced deficits in motor coordination, balance and muscle tone and facilitated motor learning in Lurche mice. View study

  • The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system ()

    Cannabidiol (CBD), the main non-psychotomimetic component of the Cannabis sativa plant, exerts therapeutically promising effects on human mental health. The objective of this study was to investigate the possible involvement of hippocampal neurogenesis in the anxiolytic effect of (CBD) in mice subjected to 14 days of chronic unpredictable stress (CUS).The findings support that the anxiolytic effect of chronic administration of (CBD) in stressed mice depends on its proneurogenic action in the adult hippocampus by facilitating endocannabinoid-mediated signaling. View study

  • Therapeutical use of the cannabinoids in psychiatry ()

    The results found in this study show that cannabidiol has therapeutic potential with antipsychotic, anxiolytic and antidepressant properties, as well as being effective under other conditions. Cannabinoids may be of great therapeutic interest for psychiatry. View study